Risk factors for treatment default in close contacts with latent tuberculous infection

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 4, 2014, Pages 421-427

  Fiske, Christina T ^a   Yan, F X ^b   Hirsch Moverman, Y ^c,g   Sterling, T ^k   Reichler, M R ^b   Bakhtawar, I ^d   LeDoux, C ^d   McAuley, J ^e   Beison, J ^e   FitzGerald, J M ^f   Naus, M ^f   Nakajima, M ^f   Schluger, N ^g   Moran, J ^g   Blumberg, H ^h   Tapia, J ^h   Singha, L ^h   Hershfeld, E ⁱ   Roche, B ⁱ   Mangura, B ^j   Sevilla, A ^j   Chavez Lindell, T ^k   Maruri, F ^k   Dorman, S ^l   Cronin, W ^l   Munk, E ^l   Chen, B ^m   Yuan, Y ^m   Yan, F ^m   Shen, Y ^m   Zhao, H ^m   Zhang, H ^m   Fagley, M ^m   Reichler, M ^m   Hirsch, C ^m   Luo, C ^m   more..

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Columbia University ^*  (United States)

^d ARKANSAS DEPARTMENT OF HEALTH   (United States)

^e RUSH UNIVERSITY   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l Maryland Department of Health   (United States)

^m NONE

more..

Author keywords

LTBI; Treatment effectiveness; Treatment non completion

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; INFECTION RISK; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS CONTROL; UNITED STATES; YOUNG ADULT; ATTITUDE TO HEALTH; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTACT EXAMINATION; MEDICATION COMPLIANCE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RISK; RISK FACTOR; STATISTICAL MODEL; TIME; TRANSMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CANADA; CHI-SQUARE DISTRIBUTION; CONTACT TRACING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84897128829     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0688     Document Type: Article

References (31)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (Suppl): S221-247.
2. Centers for Disease Control. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1989; 38: 269-272.
3. Geiter, L. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC, USA: National Academy Press, 2000.
4. Jereb J, Etkind S C, Joglar O T, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003; 7 (Suppl): S384-S390. (Pubitemid 38004714)
5. Li J, Marks S M, Driver C R, et al. Human immunodeficiency virus counseling, testing, and referral of close contacts to patients with pulmonary tuberculosis: feasibility and costs. J Public Health Manag Pract 2007; 13: 252-262. (Pubitemid 46624963)
6. Reichler M R, Reves R, Bur S, et al. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J 2002; 95: 414-420. (Pubitemid 34286737)
7. Sprinson J E, Flood J, Fan C S, et al. Evaluation of tuberculosis contact investigations in California. Int J Tuberc Lung Dis 2003; 7: S363-S368. (Pubitemid 38004711)
8. Bock N N, Metzger B S, Tapia J R, Blumberg H M. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999; 159: 295-300. (Pubitemid 29036538)
9. LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-447. (Pubitemid 37046873)
10. Priest D H, Vossel L F, Jr, Sherfy E A, Hoy D P, Haley C A. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 2004; 39: 1764-1771. (Pubitemid 39657254)
11. Lobato M N, Reves R R, Jasmer R M, Grabau J C, Bock N N, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005; 127: 1296-1303. (Pubitemid 46224294)
12. Runyon E H. Preventive treatment in tuberculosis: a statement by the Committee on Therapy, American Thoracic Society. Am Rev Respir Dis 1965; 91: 297-298.
13. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60: 555-564.
14. Martinson N A, Barnes G L, Moulton L H, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20.
15. Samandari T, Agizew T B, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
16. Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850. (Pubitemid 29488035)
17. Grzybowski S, Barnett G D, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 50 (1): 90-106.
18. Reichler M R, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287: 991-995. (Pubitemid 34252056)
19. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995; 44: 19-34.
20. Sterling T R, Villarino M E, Borisov A S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
21. Horsburgh C R, Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137: 401-409.
22. Person A K, Blain M L, Jiang H, Rasmussen P W, Stout J E. Text messaging for enhancement of testing and treatment for tuberculosis, human immunodeficiency virus, and syphilis: a survey of attitudes toward cellular phones and healthcare. Telemed J E Health 2011; 17: 189-195.
23. Jasmer R M, Saukkonen J J, Blumberg H M, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-647. (Pubitemid 35176096)
24. Page K R, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870. (Pubitemid 44455169)
25. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman L B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712-1717. (Pubitemid 46033423)
26. Menzies D, Dion M J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449. (Pubitemid 39214621)
27. Lee L M, Lobato M N, Buskin S E, Morse A, Costa O S. Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States. Int J Tuberc Lung Dis 2006; 10: 209-214. (Pubitemid 43275547)
28. Saraceni V, Pacheco A G, Golub J E, et al. Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil. Braz J Infect Dis 2011; 15: 249-252.
29. Nolan C M, Roll L, Goldberg S V, Elarth A M. Directly observed isoniazid preventive therapy for released jail inmates. Am J Respir Crit Care Med 1997; 155: 583-586. (Pubitemid 27085805)
30. Batki S L, Gruber V A, Bradley J M, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend 2002; 66: 283-293. (Pubitemid 34327864)
31. White M C, Gournis E, Kawamura M, Menendez E, Tulsky J P. Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco. Int J Tuberc Lung Dis 2003; 7: 30-35. (Pubitemid 36427028)